drugset / Trial / NCT04471441

Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.

NCT04471441

Phase 4 Completed 150 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of CertiroBell® tablet compared with mycophenolate mofetil in primary living donor liver transplant recipients.

Timeline

Start
2020-06-30
Primary completion
2024-07-24
Completion
2024-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 1 mg Oral
Comparator Mycophenolate Mofetil Small molecule 1.5 g Oral

Indications

No indication recorded.